Bond-based quadratic indices, new TOMOCOMD-CARDD molecular descriptors, and linear discriminant analysis (LDA) were used to discover novel lead trichomonacidals. The obtained LDA-based quantitative structure-activity relationships (QSAR) models, using nonstochastic and stochastic indices, were able to classify correctly 87.91% (87.50%) and 89.01% (84.38%) of the chemicals in training (test) sets, respectively. They showed large Matthews correlation coefficients of 0.75 (0.71) and 0.78 (0.65) for the training (test) sets, correspondingly. Later, both models were applied to the virtual screening of 21 chemicals to find new lead antitrichomonal agents. Predictions agreed with experimental results to a great extent because a correct classification for both models of 95.24% (20 of 21) of the chemicals was obtained. Of the 21 compounds that were screened and synthesized, 2 molecules (chemicals G-1, UC-245) showed high to moderate cytocidal activity at the concentration of 10 mg/ml, another 2 compounds (G-0 and CRIS-148) showed high cytocidal activity only at the concentration of 100 mg/ml, and the remaining chemicals (from CRIS-105 to were inactive at these assayed concentrations. Finally, the best candidate, G-1 (cytocidal activity of 100% at 10 mg/ml) was in vivo assayed in ovariectomized Wistar rats achieving promising results as a trichomonacidal drug-like compound. (Journal of Biomolecular Screening 2008:785-794).
INTRODUCTION
T RICHOMONAS VAGINALIS (TV) IS THE CAUSATIVE AGENT of the most common, nonviral, sexually transmitted disease. 1 In 1995, the World Health Organization estimated the number of adults with trichomoniasis at 170 million worldwide, more than the numbers for gonorrhea, syphilis, and chlamydia combined. 2 In 1959, a nitroimidazole derivative of a Streptomyces antibiotic, azomycin, was found to be highly effective in the systemic treatment of trichomoniasis. 3 This derivative was a,b-hydroxyethyl-2-methyl-5-nitroimidazole, commonly referred to as metronidazole (MTZ) and marketed under the trade name Flagyl.
The recommended MTZ regimen results in cure rates of approximately 95%. 4 In addition, it is remarkably safe compared with the most toxic antiprotozoal products. 5 However, resistance to MTZ has been proven to be geographically widely distributed, and no clustering or temporal trends in patients have been observed. 6 Also, in patients who do not respond to high-dose MTZ therapy, a variety of regimens have been evaluated for possible effectiveness, with rare or only occasional success. These include zinc sulfate, povidoneiodine douche, arsenicals, nonoxynol-9 cream, mebendazole, albendazole, furazolidone, and rifabutin. [7] [8] [9] [10] [11] [12] These agents, although they demonstrate considerable in vitro activity, have been clinically disappointing. Paromomycin was previously reported to be useful in the management of resistant trichomoniasis. It was used fairly effectively (cure rate, 58%) in 12 patients and remains an important option; however, local side effects were considerable and can be quite severe. 13, 14 Currently, it is clear that new trichomonacidals are needed to combat resistant Tv organisms; therefore, the main objective of this work was to use TOMOCOMD-CARDD nonstochastic and stochastic bond-based quadratic indices 15 to generate predictive linear discriminant analysis (LDA)-based quantitative structure-activity relationships (QSAR) models enabling the selection of new hits and lead drug-like compounds with antitrichomonal activity. The in vitro and in vivo evaluation of a new lead series of heterocyclic compounds with antitrichomonal activity is also presented.
MATERIALS AND METHODS

TOMOCOMD-CARDD approach
TOMOCOMD (TOpological MOlecular COMputer Design) is an interactive program for molecular design and bioinformatic research. 16 It is composed of 4 subprograms; each 1 of them allows drawing the structures (drawing mode) and calculating molecular 2D/3D (calculation mode) descriptors. In the present report, we outline salient features concerned with only 1 of its subprograms, CARDD, and with the calculation of nonstochastic and stochastic 2D bond-based quadratic indices.
Computational strategies
The main steps for the application of present method in QSAR and drug design can be briefly summarized in the following set of steps: (1) Draw the molecular pseudographs for each molecule of the data set, using the software drawing mode. (2) Use appropriated atomic properties to weight and differentiate the molecular bonds. In this study, the properties are some of those previously proposed for the calculation of the DRAGON descriptors, that is, atomic mass (M), atomic polarizability (P), atomic Mullinken electronegativity (K), van der Waals atomic volume (V). 17 The values of these atomic labels are shown in Supplemental Table 1 (Table  SM1 ). (See Supplemental Table 1 online at http://jbx .sagepub.com/supplemental/.) (3) Compute the total and local (bond and bond-type) nonstochastic and stochastic quadratic indices. (4) Find a QSAR equation by using LDA with quadratic indices as independent variables. In this sense, we can find a quantitative relation between an activity A and the linear indices having, for instance, the following appearance, A = a 0 q 0 ðwÞ + a 1 q 1 ðwÞ + a 2 q 2 ðwÞ + . . . + a k q k ðwÞ + c, where A is the measured activity, q k ðwÞ are the kth total bond-based quadratic indices, the a k s are the coefficients obtained by the linear descriminant analysis, and w represent the molecular vector. (5) Test the robustness and predictive power of the QSAR equation by using internal (cross-validation) and external (using a test set and an external predicting set) validation techniques. And (6) apply the obtained LDAbased QSAR models as cheminformatic tool for identifying leads through ligand-based virtual screening-drug discovery process.
The bond-based TOMOCOMD-CARDD descriptors computed in this study were the following:
(1) k th ðk = 0, 5Þ total nonstochastic bond-based quadratic indices not considering and considering H-atoms in the molecular graph (G) [q k ðwÞ and q H k ðwÞ, respectively].
(2) k th ðk = 0, 5Þ total stochastic bond-based quadratic indices not considering and considering H-atoms in the molecular graph (G) [ s q k ðwÞ and s q H k ðwÞ, respectively]. 
Database selection
Taking into account that the most critical aspect in the construction of a training data set is the molecular diversity of the included compounds, we selected a group of 123 organic chemicals having as much structural variability as possible. The 50 antitrichomonals considered in this study are representative of families with diverse structural patterns and action modes. Figure 1 shows a representative sample of such active compounds. On the other hand, 73 compounds having different clinical uses were selected for the set of inactive compounds, through a random selection, also guaranteeing a great structural variability. All these chemicals were taken from the Negwer handbook 18 and Merck Index, 19 where their names, synonyms, and structural formulas can be found. From these 123 chemicals, 91 were chosen at random New Antitrichomona Drug-like Chemicals to form the training set, 40 of them active and 51 inactive. The remaining subseries consisting of 10 trichomonacidals and 22 nontrichomonacidals were prepared as test sets for the external validation of the models (32 chemicals). These compounds were never used in the development of the classification models.
Data analysis and processing: linear discriminant analysis
The discriminant functions were obtained by using the LDA 20À22 as implemented in STATISTICA (version 6.0, Stat-Soft Inc., Tulsa, OK). The default parameters of this program were used in the development of the model. Forward stepwise was fixed as the strategy for variable selection. The quality of the models were determined by examining Wilks' l parameter (U-statistic), squared Mahalanobis distance (D 2 ), Fisher ratio (F), and the corresponding p-level (pðF)) as well as the percentage of good classification in the training and test sets. Models with a proportion between the number of cases and variables in the equation lower than 5 were rejected. 20 By using the models, 1 compound can then be classified as either active, if DP% > 0, being DP% = [P(Active) − P (Inactive)] × 100 or inactive otherwise. P(Active) and P(Inactive) are the probabilities with which the equations classify a compound as active and inactive, respectively.
Also a leave-group-out (LGO) cross-validation strategy was carried out. In this case, 10% of the data set was used as group size, that is, groups including 10% of the training data set were left out and predicted by the model based on the remaining 90%. This process was carried out 10 times on 10 unique independent subsets. 23 Finally, the calculation of percentages of global good classification (accuracy), sensibility, specificity (also known as ''hit rate''), false positive rate (also known as ''false alarm rate''), and Matthews correlation coefficient (C) in the training and test (predicting) sets permitted the assessment of the model. 24 
Determination of in vitro trichomonacidal activity
The biological activity was assayed on TvJH31A #4 Ref.
No. 30326 (ATCC, Bethesda, MD) in modified Diamond medium supplemented with equine serum and grown at 378C (5% CO 2 ). The compounds were added to the cultures at several concentrations (100, 10, and 1 mg/ml) after 6 h of the seeding (0 h). Viable protozoa were assessed at 24 and 48 h after incubation at 378C by using the Neubauer chamber. MTZ (Sigma-Aldrich SA, Madrid, Spain) was used as reference drug at concentrations of 2, 1, and 0.5 mg/ml. Cytocidal and cytostatic activities were determined by calculation of percentages of cytocidal (%C) and cytostatic activities (%CA), in relation to controls as previously reported. 25, 26 
Determination of in vivo trichomonacidal activity
In this study, we examined the protective efficacy of G-1 in ovariectomized rats and dealt with estradiol. 27 The excipient used to dissolve the active principle G-1 was Migliol 1 810 N (Degussa-Huls AG, Sarnia, Ontario, Canada). The taking of samples for the diagnosis of the infection was carried out previous to the intravaginal application of the 1st dose of G-1, which allowed us to know the number of rats infected before the 1st treatment. On days 7 and 8 a similar procedure was carried out, which allowed us to evaluate the effect of the 1st and 2nd doses (see Table 1 ).
RESULTS AND DISCUSSION
Development and validation of the discriminant functions
By making use of the LDA technique implemented in the STATISTICA software the following linear models were obtained, in which total as well as local nonstochastic and stochastic bond-based quadratic indices were used as independent variables: where N is the number of compounds, l is Wilks' statistics, D 2 is the square of the Mahalanobis' distance, F is the Fisher's ratio, and p is the significance level. (27 of 32) of global predictability in the prediction series, respectively. These results validate the models for use in the ligand-based virtual screening, taking into consideration that 85.0% is considered as an acceptable threshold limit for this kind of analysis. 28 In Tables SM2 and SM3 (see supplemental material) we give the names of all compounds in the training and test active and inactive sets together with their posterior probabilities calculated from the Mahalanobis distance using both equations. The same information of all compounds in the training and test inactive set appears in Table 2 , which summarizes the results of the classifications for both models in the training and test groups.
A more serious analysis was carried out by calculating most of the parameters commonly used in medical statistics (accuracy, sensitivity, specificity, and false positive rate) and the Matthews correlation coefficient (C). Table 2 also lists these parameters for both obtained models. 24, 29 Whereas the sensitivity is the probability of correctly predicting a positive example, the specificity is the probability that a positive prediction is correct. On the other hand, C quantifies the strength of the linear relation between the molecular descriptors and the classifications, and it may often provide a much more balanced evaluation of the prediction than, for instance, the percentages. 24, 29 The obtained models, equations 12 and 13, showed a high C of 0.75 (0.71) and 0.78 (0.65) in training (test) sets, which correspondingly prove the existence of a strong linear relationship because a value of + 1 implies a total linear agreement between the variables under consideration.
Although the most important criterion for the quality of the discriminant model is based on the statistics for the external prediction set, for a more exhaustive testing of the predictive power of the models, we carried out a leave-10-fold full-out (LGO) cross-validation procedure. The statistical results are depicted in Table SM4 (as supplemental material). The overall mean of the correct classification in training (test) set for this process for equations 1 and 2 was 87.69% (85.64%) and 89.03% (87.86%), correspondingly. The result of predictions on the 10% full cross-validation test evidenced the quality (robustness, stability, and predictive power) of the obtained models.
''Virtual screening'' as promissory alternative for drug discovery
One of the main features that any theoretical approach to drug discovery needs is the identification of active compounds from never-used databases of chemicals. This search can be understood as an alternative to screening approaches to drug discovery. By means of the 1st mentioned procedures, instead of essaying a large number of chemicals in a series of biological tests, one ''virtually essays'' these compounds by evaluating their activities with the models developed to this effect; this process is known today as computational (virtual or in silico) screening. 30À36 To prove the possibilities of the present approach for the ligand-based virtual screening of antitrichomonal compounds, we have selected a series of 12 compounds, as a 2nd external test set, whose activities against Tv have already been proved by several researchers. 37À39 They all were evaluated with models 1 and 2 as active/inactive ones. Its structures as well as the results of the classification are shown in Table 3 .
As can be seen, both models classify correctly most of the 12 selected compounds. The 1st model (Eq. 1) classifies only 2 chemicals incorrectly (1 of them as false positive and the other as false negative) for yielding 83.33% of correct classification, whereas the 2nd model (Eq. 2) classifies 3 chemicals incorrectly (2 of them as false positive and the other as false negative) for yielding 75.00% of correct classification. This result is a more important validation criterion for the models developed here because they were able to detect a series of compounds as active from a database composed of compounds selected from literature, and these chemicals have shown the predicted activity.
Lead discovery by ligand-based in silico screening: from dry selection to wet evaluation
To test the potential of the TOMOCOMD-CARDD method and LDA for detecting novel antiprotozoan leads, we predicted the biological activity of all the chemicals contained in our ''in-house'' collection of nitrovinyl-furans and pyridinyl substituted 7H-indeno[2.1-c]quinoline derivatives, which were provided by 2 of our synthesis research teams. 38 ;40À43 The structures of these compounds are presented in Figure 2 .
All these compounds were evaluated initially with the QSAR models 1 and 2 and then they were evaluated in vitro, to corroborate the predictions against Tv. The results for the classification and the DP% values of the compounds in these series are summarized in Table 4 . At the same time, this table also depicts the in vitro antitrichomonal activity of these 21 compounds on Tv.
In general, a good correspondence was observed between the theoretical predictions and the observed activity for both active and inactive compounds. Our trained LDA-based QSAR models (Eq. 1 and Eq. 2) successfully classified 20 of 21 compounds yielding (both) an accuracy of the 95.24%.
In these experiments, compounds G-0, G-1, UC-245, and CRIS-148 exhibited pronounced cytocidal activities at the concentrations of 100 mg/ml at 24 h, and 48 h, almost all of them showed cytocidal activity of 100%. Compounds G-1 and UC-245 maintained a good trichomonacidal (cytocidal) activity at 10 mg/ml, although only G-1 maintained a high level of percentage of reduction of Tv at concentrations of 10 mg/ml at 24 h and 48 h-100% in both periods of time. On the contrary, chemicals from CRIS-105 to CRIS-153 but New Antitrichomona Drug-like Chemicals CRIS-148 were inactive at all assayed concentrations; coinciding with model predictions. It is remarkable that these compounds did not show toxic activity in macrophages cultivations at these concentrations (see Table 4 ).
These last results can be considered as a promising starting point for the future design and refinement of novel compounds with higher antitrichomonal activity with low toxicity. Although compounds G-1, UC-245, G-0, and CRIS-148 were active at higher doses than MTZ (reference drug), this result leaves a door open to a virtual variational study of the structure of these compounds to improve their activity.
Biological ''in vivo'' assays of G-1
Wistar ovariectomized rats were used in the in vivo experiment of G-1. The results are shown in Table 5 . A total of 95% of the rats were infected at the beginning of the experiment, higher than in previous reports. 44 The product showed 100% effectiveness from the concentration of 0.125%. With 2 treatments a reduction of 50% in the infected animals was observed, and with the application of the 3rd treatment infected animals were not observed. MTZ was also used as a control in this experiment. With the application of the 2nd treatment of MTZinfected rats were not observed. The infection controls and excipient remained infected until the end of the experiment.
CONCLUSION
The obtained biosilico models permit us to classify new ''physical'' or ''virtual'' chemicals as active or inactive ones in the chemotherapy of the trichomoniasis, and they will contribute to a more rational discovery of new lead compounds with antitrichomonal activity. In fact, this report showed that by following the current procedure 4 new chemicals with potentialities (at least in in vitro assays) in antitrichomonal therapeutics were found. One of them (G-1) was even a promissory drug-like compound in the treatment of this disease in more complex living systems (rats). The identification of this new family, making use of the TOMOCOMD-CARDD approach, constitutes an The molecular structures of the compounds represented with codes are shown in Figure 2 . a, c. In silico classification obtained from Eq. 1 and Eq. 2 using nonstochastic and stochastic bond-type quadratic, respectively. b, d. Results for the classification of compounds obtained from models Eq. 1 and Eq. 2, correspondingly: DP% = [P(Active) − P(Inactive)] × 100. e. Observed (experimental activity) classification against Trichomonas vaginalis. f. Pharmacological activity of each tested compound, which was added to the cultures at doses of 100, 10, and 1 mg/ml: %CA # = cytostatic activity (24 or 48 hours) and [%C # ] = cytocidal activity (24 or 48 hours). MTZ, metronidazole (concentrations for MTZ were 2, 1, and 0.5 mg/ml, respectively). example of how this rational computer-aided method can help to reduce cost and to increase the rate in which novel chemical entities progress through the pipeline. 
